Bristol Myers Squibb (BMY) Q4 Earnings and Revenues Beat EstimatesZacks Investment Research • 02/04/21
Bristol Myers posts $10 billion loss as it books charges relating to MyoKardia and CelgeneMarket Watch • 02/04/21
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020Business Wire • 02/04/21
Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19Business Wire • 02/03/21
Bristol Myers Squibb Announces Positive Topline Results from Second Pivotal Phase 3 Psoriasis Study Showing Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast)Business Wire • 02/02/21
WuXi STA to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, SwitzerlandBusiness Wire • 02/02/21
Bristol Myers Squibb Application for Zeposia® (ozanimod) for the Treatment of Ulcerative Colitis Accepted for Filing with Priority Review by U.S. Food and Drug AdministrationBusiness Wire • 02/01/21
Amgen, Biogen, Gilead, Merck, Pfizer, and More Health Care Earnings Coming This Week24/7 Wall Street • 01/31/21
Bristol-Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should KnowZacks Investment Research • 01/25/21
U.S. Food and Drug Administration Approves OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell CarcinomaBusiness Wire • 01/22/21
Will Bristol-Myers (BMY) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 01/22/21
Bristol Myers Squibb Announces Earnings Call Time Change; Fourth Quarter 2020 Earnings Call to Occur on February 4, 2021 at 10 a.m. (Eastern Time)Business Wire • 01/21/21
U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo® (nivolumab) Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal AdenocarcinomaBusiness Wire • 01/20/21